Welcome to our dedicated page for Cencora SEC filings (Ticker: COR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Cencora, Inc. filings document material events for a NYSE-listed pharmaceutical distribution and healthcare solutions company. Recent 8-K disclosures furnish quarterly operating results, Regulation FD information, executive officer transition details, annual meeting voting results and entries into material definitive agreements.
The company’s regulatory record also covers capital-structure matters, including common stock and listed senior notes, registered public debt offerings and the terms of multiple senior note maturities. Governance filings describe director elections and other shareholder voting matters, while material-event reports connect financing activity and completed acquisitions to the company’s operating and financial disclosures.
Cencora, Inc. director Lauren M. Tyler reported two equity awards of common stock-based units. On March 5, 2026, Tyler acquired 557 shares as restricted stock units granted in lieu of a $30,000 quarterly cash retainer, with receipt of shares deferred until service ends. On January 30, 2026, Tyler acquired an additional 84 shares as an annual restricted stock unit grant received for no cash consideration, which vests in full on the first anniversary of the grant date. Both holdings are reported as directly owned.
Baumann Werner reported acquisition or exercise transactions in this Form 4 filing.
Cencora, Inc. director Werner Baumann received an annual equity award in the form of restricted stock units covering 557 shares of common stock at a reference price of $359.28 per share. The units were received for no cash consideration and will vest 100% on the first anniversary of the grant date. Following this grant, Baumann directly holds 3,687 shares of Cencora common stock.
Cencora, Inc. director Frank Clyburn reported an equity award of common stock. He acquired 557 shares of common stock, described as a grant of restricted stock units, at a reference price of $359.28 per share. The award was received for no cash consideration and is scheduled to vest 100% on the first anniversary of the grant date. Following this grant, his directly held common stock position increased to 1,724 shares.
DURCAN DERMOT MARK reported acquisition or exercise transactions in this Form 4 filing.
Cencora, Inc. director Dermot Mark Durcan reported an award of 905 shares of common stock on March 5, 2026, valued at $359.28 per share. The grant was in the form of restricted stock units received for no cash consideration and will vest 100% on the first anniversary of the grant date. Following this award, Durcan directly holds 23,767 shares of Cencora common stock.
GREENBERG LON R reported acquisition or exercise transactions in this Form 4 filing.
Cencora, Inc. director Lon R. Greenberg reported an automatic equity award. He received an annual grant of 557 restricted stock units of common stock at no cash cost. The award vests 100% on the first anniversary of the grant date, with delivery of the shares deferred until 01/15/2029.
Cencora, Inc. director Kim Lorence H. reported an acquisition of 557 shares of common stock through an annual grant of restricted stock units received for no cash consideration. The award vests 100% on the first anniversary of the grant date, with receipt of shares deferred until 3/10/2029. Following this grant, the director directly holds 4,081 common shares.
Cencora, Inc. director Redonda Miller reported an acquisition of company stock through an equity award. On the reported date, Miller received 557 restricted stock units at a reference price of $359.28 per share, increasing direct holdings to 3,751 shares. The award was received for no cash consideration, vests 100% on the first anniversary of the grant date, and delivery of the underlying shares is deferred until January 6, 2031.
Ryerkerk Lori reported acquisition or exercise transactions in this Form 4 filing.
Cencora, Inc. director Lori Ryerkerk reported receiving an equity award of 557 shares of common stock in the form of restricted stock units. The units were granted for no cash consideration and will vest 100% on the first anniversary of the grant date.
Following this award, Ryerkerk’s directly held common stock equivalent position increased to 1,073 shares, reflecting her updated ownership after the grant and before any future vesting or settlement events.
Cencora, Inc. reported the results of its 2026 Annual Meeting of Shareholders held on March 5, 2026. Shareholders elected eleven directors, with support for each nominee generally ranging from about 163 million to 168 million votes in favor, with relatively few votes against or abstentions.
Shareholders also approved, on an advisory basis, the fiscal 2025 compensation of the company’s named executive officers, with 156,852,214 votes for, 11,422,390 against, and 427,407 abstentions. In addition, they ratified the appointment of Ernst & Young LLP as independent registered public accounting firm for fiscal 2026, with 165,700,999 votes for, 12,622,687 against, and 116,893 abstentions.
Cencora, Inc. President & CEO Robert P. Mauch exercised and sold company stock in related moves. He exercised a non-qualified stock option for 3,762 shares on February 20, 2026 at an exercise price of $86.09 per share, receiving common stock. On the same day, he sold 3,762 common shares in an open-market transaction at an average price of $358.94 per share. Following these transactions, his directly held common stock position was 65,393 shares. The option had become exercisable in four equal installments on November 13, 2020, 2021, 2022, and 2023.